The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium

Human Reproduction
M L SwahnE Johannisson

Abstract

The purpose of the present study was to investigate the effect of a single dose of RU 486 administered very early in the secretory phase on endometrial development and levels of progesterone receptors, on plasma levels of gonadotrophins and ovarian hormones and on the pattern of menstrual bleeding. Twenty-four regularly menstruating subjects participated and were studied during a control, a treatment and a follow-up cycle. In the treatment cycle, a single dose of 200 mg RU 486 was given in the evening of the second day after the urinary LH peak. Plasma was collected from cycle day 10 until menstruation in both control and treatment cycles. The lengths of the control, treatment and follow-up cycles were equal. Three of the subjects had slight vaginal bleeding in association with RU 486 intake which, however, did not disturb their normal menstrual rhythm. Plasma levels of oestradiol, progesterone and FSH were not affected in the treatment cycle, whereas LH levels increased slightly. The elimination half-life of RU 486 was 28.6 h. An endometrial biopsy was taken 12, 36 or 84 h (LH + 3, LH + 4 and LH + 6) after drug intake (eight subjects in each group) and another biopsy was taken on the corresponding day in the control cycle. The...Continue Reading

Citations

Jan 1, 1992·Law, Medicine & Health Care : a Publication of the American Society of Law & Medicine·M Bygdeman, M L Swahn
Feb 1, 1993·Annals of Medicine·M BygdemanP Svalander
Jun 1, 1996·Clinical Obstetrics and Gynecology·A J MoralesA A Murphy
Oct 9, 1997·The New England Journal of Medicine·A Glasier
Jul 31, 1999·The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception·M BygdemanM L Swahn
Mar 16, 2002·Clinical Endocrinology·H O CritchleyD T Baird
Dec 17, 2008·Women's Health·Sophie OuzounianNathalie Chabbert-Buffet
Jan 1, 1991·Annals of the New York Academy of Sciences·M BygdemanM L Swahn
Nov 5, 1997·Annals of the New York Academy of Sciences·F SchatzC L Lockwood
May 27, 1993·The New England Journal of Medicine·D T Baird, A F Glasier
Jul 17, 2007·Human Reproduction Update·Frances McFarland Horne, Diana L Blithe
Nov 23, 2006·Reproductive Biology and Endocrinology : RB&E·Hilary O D CritchleyRobert M Brenner
Sep 30, 1994·Annals of the New York Academy of Sciences·K Beier-HellwigH M Beier
Nov 5, 1997·Annals of the New York Academy of Sciences·C J LockwoodF Schatz
Nov 5, 1997·Annals of the New York Academy of Sciences·D LevyP Bouchard
Aug 5, 1993·The New England Journal of Medicine·I M Spitz, C W Bardin
Jan 17, 2002·Pharmacotherapy·Melissa Sanders Wanner, Rachel L Couchenour
Jan 11, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ulrike RimmeleJan Born
Nov 5, 1999·Human Reproduction·L MarionsL Kovâcs
Dec 12, 2003·Steroids·Kristina Gemzell DanielssonMarc Bygdeman
Dec 31, 2003·Contraception·Kristina Gemzell-DanielssonLena Marions
Nov 1, 1993·Contraception·I M Spitz, C W Bardin
Mar 1, 1996·American Journal of Obstetrics and Gynecology·Y StjernholmG Ekman
Aug 19, 1994·Science·M Jitsukawa, C Djerassi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.